Text-Size:A A A+
A New York man has filed a testosterone lawsuit against Pfizer, Inc., after he allegedly suffered a dangerous blood clot following treatment with Depo-Testosterone. The complaint further alleges that the plaintiff is now at risk for cardiovascular disease, cerebrovascular accidents, and death due to his use of the testosterone replacement drug.
Depo-Testosterone is an injectable testosterone medication that was approved by the U.S. Food & Drug Administration in 1979. Like other testosterone treatments currently on the market, Depo-Testosterone is only approved to alleviate hypogonadism (low testosterone levels) associated with an underlying medical condition. But a growing number of plaintiffs have charged that it and other testosterone drugs have been used to treat low libido, weight gain and other problems typically related to male aging.
This new Depo-Testosterone lawsuit was filed on May 1st on behalf of a plaintiff who began treatment with the drug in November 2011, when he was 71 years old and in good health. In August 2012, he suffered a deep vein thrombosis, a type of blood clot that typically occurs in the legs. Such clots can break off and travel to the lungs, where they become a potentially-deadly pulmonary embolism. The lawsuit alleges that a nationwide marketing campaign undertaken by Pfizer and its Pharmacia & Upjohn Co. LLC subsidiary made misleading claims regarding the risks and benefits associated with Depo-Testosterone.
The lawsuit is just one of hundreds currently pending in U.S. courts that target the manufacturers of low testosterone therapies, including more than 1,400 cases that have been consolidated in a federal multidistrict litigation underway in Illinois. All of the lawsuits claim that sales of so-called Low-T therapies were driven by “disease mongering,” which positioned the medications as safe and effective treatments for age-related drops in testosterone. The manufacturers of the drugs are also accused of concealing their association with testosterone blood clots and other cardiovascular complications.
The current testosterone litigation got underway shortly after the FDA began reviewing their cardiovascular risks in January 2014. This past March, the FDA ordered the manufactures of testosterone treatments to add new information to their labels regarding their potential to increase a patient’s risk for heart attack and stroke.
Men who experienced heart attacks, strokes, deep vein thrombosis, pulmonary embolism or other serious cardiovascular problems that could be related to a prescription testosterone treatment can still join this growing litigation. To learn how, please call for a free legal review.